Pharmatimes have reported that Novartis’s eye treatment Jetrea has been approved by NICE who have recommended it as being cost and clinically effective.
Jetrea is a new treatment that is designed to treat the serious eye condition vitreomacular traction. This new treatment is important as the current way of treating this disease is to wait until the disease warrants surgery. The availability of Jetrea means that those unsuited to a surgical procedure will now have the opportunity for treatment before their condition deteriorates.
The drug costs £2,500 per injection and just one of which is needed for treatment